Wenda Pharma

Wenda Pharma is a clinical-stage biopharmaceutical company headquartered in Beijing, China, focused on the discovery and development of innovative small molecule drugs for oncology. The company specializes in the DNA damage response (DDR) pathway, aiming to address unmet medical needs in cancer treatment through precision medicine. Its lead candidate, WD-1603, is a highly selective and potent inhibitor of Ubiquitin Specific Peptidase 1 (USP1), currently being evaluated in Phase 1/2 clinical trials for advanced solid tumors. Wenda Pharma's research strategy leverages its proprietary DDR drug discovery platform to identify novel targets and develop therapies that can overcome resistance to existing treatments. The company is supported by leading venture capital firms and is committed to advancing a pipeline of next-generation oncology therapeutics.